Clinical Trials Browser

Phase 2 × Mesothelioma, Malignant × 30 days × Clear all

Mesothelioma, Malignant, Mesothelioma

NCT06840834 2026-03-16

Bi-MAPS

Phase 2 Recruiting

38 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT01843374 2026-03-05

Tremelimumab

Phase 2 Active not recruiting

571 enrolled 19 charts

Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT05960773 2026-03-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Phase 2 Suspended

9 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Clinical Trials

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Bi-MAPS

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Tremelimumab

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma